X

Trial Profile

Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Salmeterol/fluticasone propionate (Primary)
Indications Asthma
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

11 Aug 2009 Actual patient number (40) added as reported by ClinicalTrials.gov.
14 Jul 2008 Actual end date is now 1 Nov 2007 as reported by ClinicalTrials.gov.
14 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com